Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more) Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.


NDAQ:CARA - Post by User

Cara Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(140)
•••
Post by INVESTigator1on May 13, 2021 2:46pm
48 Views
Post# 33196164

Planet 13 and AMA/1933 Las Vegas

Planet 13 and AMA/1933 Las VegasPlanet 13 Las Vegas Regarding 1933 Industries (TGIFF)/AMA Quality and Products:

"They've combined large-scale cultivation and extraction to perfect the experience of every strain. From Black Mamba and Cookies & Cream, to GG4 and Weapon X, they take the time to produce flower that's exceptional, potent, and consistent in quality."

Keep out of reach of children. For use only by adults 21 years of age and older. Tag us in your photos to be featured! @amanev702 #ama702 #amanev

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities